Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Natural killer (NK) cells attack many tumour cell lines, and are thought to have a critical role in anti-tumour immunity; however, the interaction between NK cells and tumour targets is poorly understood. The stimulatory lectin-like NKG2D receptor is expressed by NK cells, activated CD8+ T cells and by activated macrophages in mice. Several distinct cell-surface ligands that are related to class I major histocompatibility complex molecules have been identified, some of which are expressed at high levels by tumour cells but not by normal cells in adults. However, no direct evidence links the expression of these 'induced self' ligands with tumour cell rejection. Here we demonstrate that ectopic expression of the murine NKG2D ligands Rae1beta or H60 in several tumour cell lines results in potent rejection of the tumour cells by syngeneic mice. Rejection is mediated by NK cells and/or CD8+ T cells. The ligand-expressing tumour cells induce potent priming of cytotoxic T cells and sensitization of NK cells in vivo. Mice that are exposed to live or irradiated tumour cells expressing Rae1 or H60 are specifically immune to subsequent challenge with tumour cells that lack NKG2D ligands, suggesting application of the ligands in the design of tumour vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“NKG2D has been implicated in immune surveillance of tumors using transgenic models of spontaneous cancer as well as subcutaneous tumor transfer models (Cerwenka et al., 2001; Diefenbach et al., 2001; Guerra et al., 2008).”
From p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells (2013) · cites this paper as Diefenbach et al., 2001
In the citing paper
“Previous studies from our laboratory demonstrated that transplanted tumor cells expressing NKG2D ligands are rejected by NK cells and, in some cases, T cells (Diefenbach et al., 2000, 2001, 2003)”
From p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells (2013) · cites this paper as Diefenbach et al., 2001
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Activation of NK Cells and T Cells by NKG2D, a Receptor for Stress-Inducible MICA
Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J. H., Lanier, L. L., & Spies, T. (1999) · Science · doi:10.1126/science.285.5428.727 · Cited by 2,999
Biology of Natural Killer Cells
Trinchieri, G. (1989) · Advances in Immunology · doi:10.1016/s0065-2776(08)60664-1 · Cited by 2,902
Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818 · cited 1×
“However, this was not the case with irradiated ligand-negative B16-BL6 tumour cell”
BackgroundInnate Immunity: The Virtues of a Nonclonal System of Recognition
Medzhitov, R., & Janeway, C. A. (1997) · Cell · doi:10.1016/s0092-8674(00)80412-2 · Cited by 2,434
Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy
Kärre, K., Ljunggren, H. G., Piontek, G., & Kiessling, R. (1986) · Nature · doi:10.1038/319675a0 · Cited by 2,161
Counting Antigen-Specific CD8 T Cells: A Reevaluation of Bystander Activation during Viral Infection
Murali-Krishna, K., Altman, J. D., Suresh, M., Sourdive, D. J. D., Zajac, A. J., Miller, J. D., Slansky, J., & Ahmed, R. (1998) · Immunity · doi:10.1016/s1074-7613(00)80470-7 · Cited by 1,943 · cited 1×
“IFN-γ production was assayed by stimulating CTLs or NK cells with an equal number of target cells for 5–7 h and staining intracellular IFN-γ as describe”
MethodActivating Receptors and Coreceptors Involved in Human Natural Killer Cell-Mediated Cytolysis
Moretta, A., Bottino, C., Vitale, M., Pende, D., Cantoni, C., Mingari, M. C., Biassoni, R., & Moretta, L. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.197 · Cited by 1,778 · cited 1×
“It is unknown whether engagement of NKG2D in NK cells results in direct stimulation or supplies a co-stimulatory signal that acts in conjunction with signals from other stimulatory receptor”
BackgroundDemonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice
Kaplan, D. H., Shankaran, V., Dighe, A. S., Stockert, E., Aguet, M., Old, L. J., & Schreiber, R. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7556 · Cited by 1,465
Cosman, D., Müllberg, J., Sutherland, C. L., Chin, W., Armitage, R., Fanslow, W., Kubin, M., & Chalupny, N. J. (2001) · Immunity · doi:10.1016/s1074-7613(01)00095-4 · Cited by 1,232 · cited 1×
“Several distinct cell-surface ligands that are related to class I major histocompatibility complex molecules have been identifie”
BackgroundRole of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens
Huang, A. Y. C., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., & Levitsky, H. (1994) · Science · doi:10.1126/science.7513904 · Cited by 1,160
Cited by
Items 501–600 of 1,000
Murine cytomegalovirus regulation of NKG2D ligands
Roviš, T. L., Arapović, J., Traven, L., Krmpotić, A., & Jonjić, S. (2008) · Medical Microbiology and Immunology · doi:10.1007/s00430-008-0080-7 · Cited by 50
Overcoming immune tolerance to cancer by heat shock protein vaccines.
Liu, B., DeFilippo, A. M., & Li, Z. (2002) · PubMed · Cited by 42
Dynamical Behaviour of a Tumor-Immune System with Chemotherapy and Optimal Control
Sharma, S., & Samanta, G. P. (2013) · Journal of Nonlinear Dynamics · doi:10.1155/2013/608598 · Cited by 41
Pollock, R. A., Chandran, V., Barrett, J., Eder, L., Pellett, F., Yao, C. M. K. L., Lino, M., Shanmugarajah, S., Farewell, V. T., & Gladman, D. D. (2011) · Tissue Antigens · doi:10.1111/j.1399-0039.2011.01670.x · Cited by 42
DNA damage, tumor mutational load and their impact on immune responses against cancer
Liontos, M., Anastasiou, I. P., Bamias, A., & Dimopoulos, M. A. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.07.11 · Cited by 43
“Also, overexpression of NKG2D ligands in cancer cells causes tumor rejection in mice (25) and NKG2D-deficient animals are defective in tumor surveillance in models of spontaneous malignancy (26).”
BackgroundNKG2D and Related Immunoreceptors
Strong, R. K., & McFarland, B. J. (2004) · Advances in protein chemistry · doi:10.1016/s0065-3233(04)68008-9 · Cited by 44
“62, 71, 73-75 It has been shown that tumors expressing RAE-1 molecules can be recognized by NK cells and rejected.(62) Like huNKG2D–MIC stimulation of NK cells, RAE-1 mediated rejection can override inhibitory signals from the expression of self MHC class I proteins on tumor cells.”
BackgroundDifferent Strategies for Cancer Treatment: Mathematical Modelling
Isaeva, O. G., & Osipov, V. A. (2008) · Computational and Mathematical Methods in Medicine · doi:10.1080/17486700802536054 · Cited by 41
“Finally, to simulate vaccine therapy we alter the corresponding model parameters in the same direction as they change in Diefenbach’s murine model [14] (cf.”
Tsukagoshi, M., Wada, S., Yokobori, T., Altan, B., Ishii, N., Watanabe, A., Kubo, N., Saito, F., Araki, K., Suzuki, H., et al. (2015) · Cancer Science · doi:10.1111/cas.12853 · Cited by 43
Immunophenotyping of Stage III Melanoma Reveals Parameters Associated with Patient Prognosis
Jacquelot, N., Roberti, M. P., Enot, D. P., Rusakiewicz, S., Semeraro, M., Jégou, S., Flores, C., Chen, L., Kwon, B. S., Borg, C., et al. (2016) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2015.12.042 · Cited by 42
“Tumoral NKG2D and blood PDL-1 expression on CD8D T cells influence OS in stage III MM NKG2D is an important activating receptor associated with cytolytic functions of CTL and NK cells (Diefenbach et al., 2001).”
Activation of Natural Killer Cells: Underlying Molecular Mechanisms Revealed
Backström, E., Kristensson, K., & Ljunggren, H. (2004) · Scandinavian Journal of Immunology · doi:10.1111/j.0300-9475.2004.01475.x · Cited by 52
Myeloid-Derived Suppressor–Cell Dynamics Control Outcomes in the Metastatic Niche
Kreger, J., Torres, E. T. R., & MacLean, A. L. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0617 · Cited by 43
TNF Neutralization Results in the Delay of Transplantable Tumor Growth and Reduced MDSC Accumulation
Atretkhany, K. N., Nosenko, M. A., Gogoleva, V. S., Zvartsev, R. V., Qin, Z., Nedospasov, S. A., & Drutskaya, M. S. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00147 · Cited by 43
Tamaki, S., Kawakami, M., Yamanaka, Y., Shimomura, H., Imai, Y., Ishida, J., Yamamoto, K., Ishitani, A., Hatake, K., & Kirita, T. (2008) · Clinical Immunology · doi:10.1016/j.clim.2008.09.004 · Cited by 43
Re-educating natural killer cells
Sun, J. C.-Y. (2010) · The Journal of Experimental Medicine · doi:10.1084/jem.20101748 · Cited by 48
Intact NKG2D-Independent Function of NK Cells Chronically Stimulated with the NKG2D Ligand Rae-1
Champsaur, M., Beilke, J. N., Ogasawara, K., Koszinowski, U. H., Jonjić, S., & Lanier, L. L. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000397 · Cited by 42
“Indeed, ectopic expression of NKG2D ligands on tumors renders them susceptible to NK cell killing in vitro and in vivo (14, 15).”
BackgroundMathematical model of cancer treatments using immunotherapy, chemotherapy and biochemotherapy
Mamat, M., Subiyanto, S., & Kartono, A. (2013) · Applied Mathematical Sciences · doi:10.12988/ams.2013.13023 · Cited by 55
Langerhans cells and NK cells cooperate in the inhibition of chemical skin carcinogenesis
Ortner, D., Tripp, C. H., Komenda, K., Dubrac, S., Zelger, B., Hermann, M., Doppler, W., Tymoszuk, P., Boon, L., Clausen, B. E., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1260215 · Cited by 41
“In fact, NKG2D-ligation by NK cells represents a major mechanism for the detection and elimination of pre-malignant cells.(6) Moreover, NK cells displayed a mature phenotype in the epidermis since they were CD11bCCD27¡, a phenotype also exhibited by NK cells in other peripheral tissues.”
BackgroundSchwaiger, T., Knittler, M. R., Grund, C., Angela, R. O.-O. O., Kapp, J., Lerch, M. M., Mettenleiter, T. C., Mayerle, J. V., & Blohm, U. (2017) · International Journal of Cancer · doi:10.1002/ijc.31026 · Cited by 43
“In a variety of other cancer types and cell lines Rae-1d or related proteins expressed by the retinoic acid early inducible gene family are upregulated and serve as activating ligands for NK cells.(38,39) However, in DT6606PDA cells Rae-1d was only marginally expressed but inducible by NDV.”
Mathematical modeling of regulatory T cell effects on renal cell carcinoma treatment
de Pillis, L. G., Caldwell, T., Sarapata, E., & Williams, H. (2013) · Discrete and Continuous Dynamical Systems - B · doi:10.3934/dcdsb.2013.18.915 · Cited by 39
“However, it is possible that certain treatments may effectively reduce this parameter value, representing a strengthening of the immune response [15, 20].”
BackgroundIs the allee effect relevant to stochastic cancer model?
Sardar, M., & Khajanchi, S. (2021) · Journal of Applied Mathematics and Computing · doi:10.1007/s12190-021-01618-6 · Cited by 39
NK Cell Anti-Tumor Surveillance in a Myeloid Cell-Shaped Environment
Russo, E., Laffranchi, M., Tomaipitinca, L., Prete, A. D., Santoni, A., Sozzani, S., & Bernardini, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.787116 · Cited by 40
“Indeed, depletion of NK cells in mice bearing transplantation- or carcinogen-induced tumors leads to enhanced tumor aggressiveness and spreading (16, 17).”
BackgroundEffect of azithromycin on natural killer cell function
Lin, S., Yan, D., Lee, W., Kuo, M., Hsiao, H.-S., & Lee, P.-Y. (2012) · International Immunopharmacology · doi:10.1016/j.intimp.2012.02.013 · Cited by 39
NKG2D-independent suppression of T cell proliferation by H60 and MICA
Kriegeskorte, A. K., Gebhardt, F. E., Porcellini, S., Schiemann, M., Stemberger, C., Franz, T. J., Huster, K. M., Carayannopoulos, L. N., Yokoyama, W. M., Colonna, M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502026102 · Cited by 43
Mathematical modeling of tumor growth: the MCF-7 breast cancer cell line
Wei, H. (2019) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2019325 · Cited by 43
Wu, J., Chen, Z., Wickström, S. L., Gao, J., He, X., Xu, J., Wu, J., Du, Q., Yang, M., Chen, Y., et al. (2021) · Advanced Science · doi:10.1002/advs.202101029 · Cited by 43
Hu, J., Zhu, S., Xia, X., Zhang, L., Kleinerman, E. S., & Li, S. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-34 · Cited by 38
“NKG2D ligands are primarily present in tumor cells or infected cells but not in normal tissues [17,33,34].”
BackgroundNatural killer cells in non-hematopoietic malignancies
Desbois, M., Rusakiewicz, S., Locher, C., Zitvogel, L., & Chaput, N. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00395 · Cited by 42
“, 2001), NK group 2 member D (NKG2D) activating receptors (Diefenbach et al., 2001), DNAX accessory molecule-1 (DNAM-1; Lakshmikanth et al.”
BackgroundKoh, C. Y., Ortaldo, J. R., Blazar, B. R., Bennett, M., & Murphy, W. J. (2003) · Blood · doi:10.1182/blood-2003-04-1367 · Cited by 38
NKG2D in Innate and Adaptive Immunity
Lanier, L. L. (2005) · Advances in experimental medicine and biology · doi:10.1007/0-387-24180-9_7 · Cited by 39
Cellular immunity and immunotherapy of brain tumors
Robert, M. P. (2004) · Frontiers in bioscience · doi:10.2741/1465 · Cited by 38
Belting, L., Hömberg, N., Przewoznik, M., Brenner, C., Riedel, T., Flatley, A., Polić, B., Busch, D. H., Röcken, M., & Mocikat, R. (2015) · European Journal of Immunology · doi:10.1002/eji.201445375 · Cited by 40
Navarro, A. G., Espedal, H., Joseph, J. V., Trachsel-Moncho, L., Bahador, M., Gjertsen, B. T., Kristoffersen, E. K., Simonsen, A., Miletić, H., Enger, P. Ø., et al. (2019) · Cancers · doi:10.3390/cancers11070996 · Cited by 43
“, major histocompatibility complex (MHC) chain-related antigens (MICA/B) and the UL16-binding proteins (ULBPs) [20,21].”
BackgroundRegulation of tumor angiogenesis by the crosstalk between innate immunity and endothelial cells
Ebeling, S., Kowalczyk, A., Pérez-Vázquez, D., & Mattiola, I. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1171794 · Cited by 39
“NKG2D is an activating receptor expressed by NK cells that has an important role in NK cell-dependent tumor immunity, including resistance to metastasis (115).”
BackgroundCancer Immunoediting of the NK Group 2D Ligand H60a
O’Sullivan, T. E., Dunn, G. P., LaCoursiere, D. Y., Schreiber, R. D., & Bui, J. D. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100413 · Cited by 37
“Because it is known that NK cell activation and killing can lead to T cell priming (23, 44), we envision that NK/NKG2D-dependent killing of H60a-hi cells releases Ags that are targeted in an adaptive immune response to H60a-lo cells, leading to complete tumor rejection.”
BackgroundInfluentialNK cell receptors in antiviral immunity
Moser, J. M., Byers, A. M., & Lukacher, A. E. (2002) · Current Opinion in Immunology · doi:10.1016/s0952-7915(02)00357-6 · Cited by 39
Girardi, M., Oppenheim, D. E., Glusac, E. J., Filler, R. B., Balmain, A., Tigelaar, R. E., & Hayday, A. (2004) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2004.22342.x · Cited by 40
Natural killer cell‐mediated lysis of freshly isolated human tumor cells
Carlsten, M., Malmberg, K., & Ljunggren, H. (2008) · International Journal of Cancer · doi:10.1002/ijc.24082 · Cited by 38
“, for NKG2D-mediated triggering of some MHC Class I expressing tumor cell lines.(40,41)”
BackgroundImmune Control in Hepatocellular Carcinoma Development and Progression: Role of Stromal Cells
Sprinzl, M. F., & Galle, P. R. (2014) · Seminars in Liver Disease · doi:10.1055/s-0034-1394138 · Cited by 38
Miller, T. W., Amason, J., Garcin, E. D., Lamy, L., Dranchak, P. K., MacArthur, R., Braisted, J. C., Rubin, J. S., Burgess, T. L., Farrell, C. L., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0218897 · Cited by 37
NK Cell Interaction With Platelets and Myeloid Cells in the Tumor Milieu
Maurer, S., & de Andrade, L. F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.608849 · Cited by 37
“Platelets Promote the Shedding of NKG2D Ligands by Tumor Cells High levels of NKG2DL tip the balance toward NK cell activation (28, 29).”
BackgroundIRF-1 Expression Is Essential for Natural Killer Cells to Suppress Metastasis
Ksienzyk, A., Neumann, B., Nandakumar, R., Finsterbusch, K., Grashoff, M., Zawatzky, R., Bernhardt, G., Häuser, H., & Kröger, A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1565 · Cited by 41
“Earlier studies indicated that expression of NKG2D ligands results in NK cell-mediated tumor cell killing even when the tumor cells express normal levels of MHC molecules (35, 36).”
BackgroundA mixed radiotherapy and chemotherapy model for treatment of cancer with metastasis
Ghaffari, A., Bahmaie, B., & Nazari, M. (2016) · Mathematical Methods in the Applied Sciences · doi:10.1002/mma.3887 · Cited by 36
“Primed with ligand-transduced cells, [54] challenged with ligand-transduced cells (in primary tumor) k1 cell 2 Steepness coefficient of the 3.”
BackgroundInfluentialChang, C., & Ferrone, S. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.07.001 · Cited by 38
NKG2D splice variants: a reexamination of adaptor molecule associations
Rabinovich, B. A., Li, J. S. Y., Wolfson, M. F., Lawrence, W., Beers, C., Chalupny, J., Hurren, R., Greenfield, B., Miller, R. G., & Cosman, D. J. (2006) · Immunogenetics · doi:10.1007/s00251-005-0078-x · Cited by 41
“In a mouse tumor model, ectopic expression of Rae-1 on tumor cells (EL4, RMA, B16) renders them sensitive to in vivo clearance, a phenomenon that involves both NK cells and T cells (Cerwenka et al. 2001; Diefenbach et al. 2001).”
BackgroundDu, C., Bevers, J. J., Cook, R., Lombana, T. N., Rajasekaran, K., Matsumoto, M. L., Spiess, C., Kim, J. M., & Ye, Z. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0687-9 · Cited by 35
Cellular liaisons of natural killer lymphocytes in immunology and immunotherapy of cancer
Arina, A., Murillo, O., Dubrot, J., Azpilikueta, A., Alfaro, C., Perez‐Gracia, J. L., Bendandi, M., Palencia, B., Hervás‐Stubbs, S., & Melero, I. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.5.599 · Cited by 39
“Rejection of tumor cells in vivo occurred even if they expressed normal levels of MHC-I molecules [57,58], and was mediated by both NK and CD8+ T cells [57].”
BackgroundRequirements for control of B‐cell lymphoma by NK cells
Brenner, C. D., King, S. B. S., Przewoznik, M., Wolters, I., Adam, C., Bornkamm, G. W., Busch, D. H., Röcken, M., & Mocikat, R. (2009) · European Journal of Immunology · doi:10.1002/eji.200939937 · Cited by 46
Chronotherapy of colorectal cancer
Giacchetti, S. (2002) · Chronobiology International · doi:10.1081/cbi-120002602 · Cited by 36
Belicha‐Villanueva, A., Riddell, J. R., Bangia, N., & Gollnick, S. O. (2012) · Lasers in Surgery and Medicine · doi:10.1002/lsm.21160 · Cited by 36
Human Natural Killer Receptors, Co‐Receptors, and Their Ligands
Biassoni, R., & Malnati, M. (2018) · Current Protocols in Immunology · doi:10.1002/cpim.47 · Cited by 37
Maccalli, C., Nonaka, D., Piris, A., Pende, D., Rivoltini, L., Castelli, C., & Parmiani, G. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1166 · Cited by 38
Beilke, J. N., & Gill, R. G. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007040423 · Cited by 34
Maintaining the Balance: Regulation of NK Cell Activity
Imširović, V., Wensveen, F. M., Polić, B., & Jelenčić, V. (2024) · Cells · doi:10.3390/cells13171464 · Cited by 34
“It was shown that transfection of resistant tumors with NKG2D ligands makes them susceptible to NK cell-mediated control in vivo and in vitro [34,35].”
BackgroundSadegh, L., Chen, P. W., Brown, J. R., Han, Z., & Niederkorn, J. Y. (2015) · International Journal of Cancer · doi:10.1002/ijc.29480 · Cited by 33
Paschen, A., Baingo, J., & Schadendorf, D. (2014) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2014.01.009 · Cited by 35
Tršan, T., Busche, A., Abram, M., Wensveen, F. M., Lemmermann, N. A. W., Arapović, M., Babić, M., Tomić, A., Golemac, M., Brinkmann, M. M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1310215110 · Cited by 33
“The promoting effect of NKG2D ligands on specific CD8 T-cell responses is not without precedent in the literature: it has been shown that NKG2D ligands RAE-1 and H60 ectopically expressed on tumor cell lines strongly enhance the generation of tumor-specific CD8 T-cell response and are able to protect an immunized host…”
BackgroundJachimowicz, R. D., Fracasso, G., Yazaki, P. J., Power, B. E., Borchmann, P., Engert, A., Hansen, H. P., Reiners, K. S., Madlener, M., von Strandmann, E. P., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-1093 · Cited by 35
George, C. N., Canuas-Landero, V., Theodoulou, E., Muthana, M., Wilson, C., & Ottewell, P. D. (2020) · Journal of bone oncology · doi:10.1016/j.jbo.2020.100317 · Cited by 34
Immunotherapeutic targeting of activating natural killer cell receptors and their ligands in cancer
Peipp, M., Klausz, K., Boje, A. S., Zeller, T., Zielonka, S., & Kellner, C. (2022) · Clinical & Experimental Immunology · doi:10.1093/cei/uxac028 · Cited by 39
Charni, S., Aguilo, J. I., Garaude, J., de Bettignies, G., Jacquet, C., Hipskind, R. A., Singer, D. S., Anel, A., & Villalba, M. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803006 · Cited by 33
“NKG2D ligands induce NK cell recruitment, even to MHC-I-expressing tumor cells (26).”
BackgroundDissecting the Role of Bone Marrow Stromal Cells on Bone Metastases
Buenrostro, D., Park, S. I., & Sterling, J. A. R. (2014) · BioMed Research International · doi:10.1155/2014/875305 · Cited by 33
Walsh, K. B., Lanier, L. L., & Lane, T. E. (2007) · Journal of Virology · doi:10.1128/jvi.02033-07 · Cited by 40
“The interaction between the NKG2D receptor and specific ligands results in enhanced effector functions by NK cells, including the secretion of IFN- and cytotoxic activity that augments the killing of NKG2D ligand-bearing target cells (14, 15, 20, 21, 57).”
Bolanos, F. D., & Tripathy, S. K. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003046 · Cited by 33
Regulation of Human DAP10 Gene Expression in NK and T Cells by Ap-1 Transcription Factors
Marusina, A. I., Burgess, S. J., Pathmanathan, I., Borrego, F., & Coligan, J. E. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.1.409 · Cited by 34
“The expression of NKG2D/DAP10 ligands by such stressed cells makes them susceptible to killing by NK and CD8 T cells (9, 14, 15).”
BackgroundMitra, R., Singh, S., & Khar, A. (2003) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399403005623 · Cited by 37
Natural killer cell receptors: Regulating innate immune responses to hematologic malignancy
Hsu, K. C., & Dupont, B. (2005) · Seminars in Hematology · doi:10.1053/j.seminhematol.2005.01.010 · Cited by 34
Kowalczyk, A., Wierzbicki, A. J., Gil, M., Bambach, B. J., Kaneko, Y., Rokita, H., Repasky, E. A., Fenstermaker, R. A., Brecher, M. L., Ciesielski, M. J., et al. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0289-0 · Cited by 33
“delivery of a costimulatory signal that leads to memory cell formation [13].”
BackgroundKilling the Invaders: NK Cell Impact in Tumors and Anti-Tumor Therapy
Molgora, M., Cortez, V. S., & Colonna, M. (2021) · Cancers · doi:10.3390/cancers13040595 · Cited by 33
“NKG2Ddeficient (Klrk1−/−) mice are more susceptible to the development of several types of primary tumors, such as a transgene-driven lymphoma and prostate carcinoma, and the overexpression of NKG2D ligands is protective in models of transplanted tumors [14,21,25].”
BackgroundFusion Proteins of NKG2D/NKG2DL in Cancer Immunotherapy
Ding, H., Yang, X., & Wei, Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010177 · Cited by 33
“Other NKG2DLs include UL16 binding proteins (ULBPs) [9] in human and mouse, murine UL16-binding protein-like transcript 1 (MULT1) [10], retinoic acid early transcript 1 (Rae1) [11,12] and histocompatibility antigen 60 (H60) [13] in mouse.”
BackgroundModeling immune cell behavior across scales in cancer
Makaryan, S. Z., Cess, C. G., & Finley, S. D. (2020) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1484 · Cited by 36
“Model parameters were taken from previous modeling works, and the predicted number of tumor cells over time was compared to data from an in vivo mouse study (Diefenbach, Jensen, Jamieson, & Raulet, 2001).”
MethodMantovani, S., Varchetta, S., Mele, D., Donadon, M., Torzilli, G., Soldani, C., Franceschini, B., Porta, C., Chiellino, S., Pedrazzoli, P., et al. (2020) · Cancers · doi:10.3390/cancers12123583 · Cited by 34
Adaptive NK Cell Therapy Modulated by Anti-PD-1 Antibody in Gastric Cancer Model
Abdolahi, S., Ghazvinian, Z., Muhammadnejad, S., Ahmadvand, M., Aghdaei, H. A., Ebrahimi‐Barough, S., Ai, J., Zali, M. R., Verdi, J., & Baghaei, K. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.733075 · Cited by 31
Rajasekaran, K., Chu, H., Kumar, P., Xiao, Y., Tinguely, M., Samarakoon, A., Kim, T. W., Li, X., Thakar, M. S., Zhang, J., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.261917 · Cited by 31
Dambrauskas, Ž., Svensson, H., Joshi, M. G., Hyltander, A. G., Naredi, P. L. J., & Iresjö, B. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.2156 · Cited by 31
“Tumor cells that stably express NKG2D ligands at high level may be rejected by CD8 T cells and/or NK cells and mice immunized with NKG2/D ligand-transfected tumor cells were reported to develop adaptive immunity against re-challenge with the parental tumor cell lines (22,23).”
BackgroundMusso, A., Catellani, S., Canevali, P., Tavella, S., Venè, R., Boero, S., Pierri, I., Gobbi, M., Kunkl, A., Ravetti, J., et al. (2013) · Haematologica · doi:10.3324/haematol.2013.097311 · Cited by 31
“Recognition of these molecules, also called NKG2D ligands (NKG2D-L), is mediated by the NKG2D receptor, expressed on both αβ and gd T cells.(7,9-11) Another type of gd T-cell activation is represented by antibody-opsonized cells or micro-organisms through the binding of IgG Fc by the Fcg receptor III CD16, which media…”
BackgroundChen, Y., Lin, W., Zhu, W., Lin, J., Zhou, Z., Huang, C., Chen, G., Shi, Y., Guo, Z., & Ye, Y. (2015) · Immunologic Research · doi:10.1007/s12026-015-8743-0 · Cited by 31
“system in vivo as the tumor evolves [29, 30].”
BackgroundClinical impact of natural killer cell reconstitution after allogeneic hematopoietic transplantation
Velardi, A., Ruggeri, L., Mancusi, A., Burchielli, E., Perruccio, K., Aversa, F., Martelli, M. F., & on behalf of the Immunobiology Working Party of the European Group for Blood and Marrow Transplantation (EBMT) (2008) · Seminars in Immunopathology · doi:10.1007/s00281-008-0136-1 · Cited by 33
Brehm, M. A., Daniels, K. A., Ortaldo, J. R., & Welsh, R. M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.11.6663 · Cited by 33
Cutting Edge: The Minor Histocompatibility Antigen H60 Peptide Interacts with Both H-2Kb and NKG2D
Cerwenka, A., O’Callaghan, C. A., Hamerman, J. A., Yadav, R., Ajayi, W. U., Roopenian, D. C., Joyce, S., & Lanier, L. L. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.7.3131 · Cited by 31
Regulation of Natural Killer Cell Function
Makrigiannis, A. P., & Anderson, S. K. (2003) · Cancer Biology & Therapy · doi:10.4161/cbt.2.6.560 · Cited by 33
Immune ULBP1 is Elevated in Colon Adenocarcinoma and Predicts Prognosis
Ruan, G., Xie, H., Zhu, L., Ge, Y., Lin, Y., Liao, C., Gong, Y., & Shi, H. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.762514 · Cited by 30
“In the mouse model, the tumor cell line of transfection of RaE1 is rejected by NKG2D-mediated immunization (Diefenbach et al., 2001).”
BackgroundStamova, S., Koristka, S., Keil, J., Arndt, C., Feldmann, A., Michalk, I., Bartsch, H., Bippes, C. C., Schmitz, M., Cartellieri, M., et al. (2012) · Antibodies · doi:10.3390/antib1020172 · Cited by 34
“Based on the observation that tumor cells expressing high levels of NKG2D ligands were more susceptible to NK cell mediated killing, whereas tumor cells expressing low or intermediate levels of NKG2D ligands were less immunogenic [142], a promising strategy to activate efficiently anti-tumor immune responses and to ov…”
BackgroundEpigenetic Mechanisms Dictating Eradication of Cancer by Natural Killer Cells
Bugide, S., Janoštiak, R., & Wajapeyee, N. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.06.004 · Cited by 33
Restoration of antitumor immunity through anti-MICA antibodies elicited with a chimeric protein
Torres, N., Regge, M. V., Secchiari, F., Friedrich, A. D., Spallanzani, R. G., Raffo Iraolagoitia, X. L., Núñez, S. Y., Sierra, J. M., Ziblat, A., Santilli, M. C., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000233 · Cited by 29
NKG2D-bispecific enhances NK and CD8+ T cell antitumor immunity
Hérault, A., Mak, J., Cruz-Chuh, J. D., Dillon, M. A., Ellerman, D. A., Go, M., Cosino, E., Clark, R., Carson, E., Yeung, S., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03795-2 · Cited by 30
“NKG2D plays a critical role in tumor immune surveillance and eradication as shown by NKG2D ligand overexpression [17, 18], antibody-mediated neutralization of NKG2D [19] and NKG2D-deficient mice [20].”
BackgroundSatwani, P., Bavishi, S., Saha, A., Zhao, F., Ayello, J. S., van de Ven, C., Chu, Y., & Cairo, M. S. (2014) · Cytotherapy · doi:10.1016/j.jcyt.2014.03.008 · Cited by 30
Jensen, H., Andresen, L. O., Nielsen, J., Christensen, J. P., & Skov, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023023 · Cited by 29
Imbalance of NKG2D and its inhibitory counterparts: How does tumor escape from innate immunity?
Zhang, C., Zhang, J., Wei, H., & Tian, Z. (2005) · International Immunopharmacology · doi:10.1016/j.intimp.2005.03.003 · Cited by 29
Bonmort, M., Ullrich, E., Mignot, G., Jacobs, B., Chaput, N., & Zitvogel, L. (2007) · Biochimie · doi:10.1016/j.biochi.2007.04.014 · Cited by 29
Block, M. S., & Markovic, S. N. (2009) · American Journal of Immunology · doi:10.3844/ajisp.2009.29.49 · Cited by 32
“NKG2D recognizes a host of MHC class I-like protein ligands, including MHC class I-chain-related protein (MIC) A and MIC B([70]) and the Retinoic Acid Early inducible-1 (RAE-1) family of proteins([71]).”
BackgroundA mathematical model of cell-mediated immune response to tumor
Song, G., Tian, T., & Zhang, X. (2020) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2021020 · Cited by 28
Escape from NK cell tumor surveillance by NGFR-induced lipid remodeling in melanoma
Lehmann, J., Caduff, N., Krzywińska, E., Stierli, S., Salas-Bastos, A., Loos, B., Levesque, M. P., Dummer, R., Stockmann, C., Münz, C., et al. (2023) · Science Advances · doi:10.1126/sciadv.adc8825 · Cited by 30
“Depletion or inhibition of NK cells in immunocompetent mice increases metastasis ( 13 , 14 ), whereas NK cell adoptive transferand activation of NK cells counteract metastatic dissemination ( 15 , 16 ).”
The balancing act: Inhibitory Ly49 regulate NKG2D-mediated NK cell functions
Malarkannan, S. (2006) · Seminars in Immunology · doi:10.1016/j.smim.2006.04.002 · Cited by 33
“Under challenged conditions, target cells express a family of stress-inducible ligands, including ULBP [31,32], MICA/B in humans [33], and H60 [34,35], Rae-1 [36], and Mult-1 [37,38] in mice, which are recognized by the activating receptor, NKG2D [34,39–42].”
BackgroundHoover, R. G., Gullickson, G., & Kornbluth, J. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00393 · Cited by 29
“The first, RMA-S, a murine T cell lymphoma, is a wellcharacterized NK-sensitive hematopoietic tumor (Karre et al., 1986; Kim et al., 2000; Diefenbach et al., 2001).”
Four novel ULBP splice variants are ligands for human NKG2D
Cao, W., Xi, X., Wang, Z., Dong, L., Hao, Z., Cui, L., Ma, C., & He, W. (2008) · International Immunology · doi:10.1093/intimm/dxn057 · Cited by 28
Pedde, A., Kim, H., Donakonda, S., Baumann, T., Bayerl, F., Meiser, P., Hirschberger, A., Klement, C., Grassmann, S. A., Öllinger, R., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114855 · Cited by 27
Conditional Deletion of PGC-1α Results in Energetic and Functional Defects in NK Cells
Gerbec, Z. J., Hashemi, E., Nanbakhsh, A., Holzhauer, S., Yang, C., Mei, A., Tsaih, S., Lemke, A., Flister, M. J., Riese, M. J., et al. (2020) · iScience · doi:10.1016/j.isci.2020.101454 · Cited by 28
Mehdizadeh, R., Shariatpanahi, S. P., Goliaei, B., & Rüegg, C. (2023) · Scientific Reports · doi:10.1038/s41598-023-32554-z · Cited by 27
MCMV avoidance of recognition and control by NK cells
Brizić, I., Roviš, T. L., Krmpotić, A., & Jonjić, S. (2014) · Seminars in Immunopathology · doi:10.1007/s00281-014-0441-9 · Cited by 27
“have demonstrated that tumors ectopically expressing NKG2D ligands, RAE-1β and H60, induce potent T cell response and sensitize NK cells in vivo [91].”
The role of natural killer cells in periodontitis
Wilensky, A., Chaushu, S., & Shapira, L. (2015) · Periodontology 2000 · doi:10.1111/prd.12092 · Cited by 27
Metadata
- Authors
- Diefenbach, A., Jensen, E. R., Jamieson, A. M., & Raulet, D. H.
- Affiliations
- University of California, Berkeley (US)
- Corresponding author
- Raulet, David H.
- Venue
- Nature
- Published
- 2001-09-13
- Volume
- 413
- Issue
- 6852
- Pages
- 165-171
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3900321
- OpenAlex
- W1595098530
- Cited by
- 1,083
- References
- 30
- Citations by year
- 2026: 17 · 2025: 28 · 2024: 26 · 2023: 38 · 2022: 28 · 2021: 43 · 2020: 48 · 2019: 37 · 2018: 38 · 2017: 32 · 2016: 34 · 2015: 53 · 2014: 42 · 2013: 48 · 2012: 42
- FWCI
- 15.26
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Canadian Institutes of Health Research
- National Institute of Allergy and Infectious Diseases (R01AI039642)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- NKG2D, Rae1, NKG2D ligands, natural killer cells, tumour immunity, tumor rejection, CD8+ T cells, cancer vaccines, MHC class I
- MeSH terms
- Animals, Cytotoxicity, Immunologic, Immunity, Killer Cells, Natural, Ligands, Membrane Proteins, Mice, Inbred C57BL, Neoplasms, Receptors, Immunologic, Recombinant Proteins, T-Lymphocytes, Cytotoxic, Tumor Cells, Cultured, Minor Histocompatibility Antigens, CD8-Positive T-Lymphocytes, Mice, Receptors, Natural Killer Cell, NK Cell Lectin-Like Receptor Subfamily K
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.